<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Lung transplantation: Deceased donor evaluation</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Lung transplantation: Deceased donor evaluation</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Lung transplantation: Deceased donor evaluation</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Remzi Bag, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Maher A Baz, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Robert M Kotloff, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Paul Dieffenbach, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jul 20, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Optimal selection and care of donor lungs for transplant are needed to increase the number of successful lung transplantations. Deceased donor evaluation and selection after brain and cardiac death will be reviewed here from the lung transplant perspective.</p><p>Lobar lung procurement from living donors is exceedingly rare; living donor eligibility and selection is beyond the scope of this topic. The general approach to potential deceased organ donors including identification of donors, referral to organ procurement organizations (OPO), and the differing responsibilities of the treating providers and the OPO are discussed separately. Management of the deceased organ donor before and during procurement is also covered elsewhere.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/4660.html" rel="external">"Lung transplantation: Disease-based choice of procedure"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/114280.html" rel="external">"Evaluation of the potential deceased organ donor (adult)"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/114018.html" rel="external">"Management of the deceased organ donor"</a>.)</p><p></p><p>The indications for lung transplantation, selection of lung transplant recipients, and techniques for lung procurement and preservation are reviewed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/4659.html" rel="external">"Lung transplantation: An overview"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/4658.html" rel="external">"Lung transplantation: General guidelines for recipient selection"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/4652.html" rel="external">"Lung transplantation: Donor lung procurement and preservation"</a>.)</p><p></p><p class="headingAnchor" id="H2"><span class="h1">DONATION AFTER BRAIN DEATH</span><span class="headingEndMark"> — </span>Most allografts from deceased donors are procured following declaration of death by neurologic criteria, referred to as "donation after brain death" (DBD) or "donation after neurologic determination of death" (DNDD). Donor evaluation begins with the notification of the local organ procurement organization (OPO) of a potential donor. A member of the OPO, or a provider trained in the consent of families for organ donation, should approach the family as soon as reasonable after the determination of brain death [<a href="#rid1">1</a>]. (See  <a class="medical medical_review" href="/d/html/4831.html" rel="external">"Diagnosis of brain death"</a>.)</p><p>When the patient has signed an irrevocable consent for transplant (offered through some state registries), the OPO staff will support the family through the organ retrieval and grieving process. If consent has not already been provided by the patient, the OPO staff will explain the procurement process to the family, including the dignity of the process and implications for funeral arrangements, and obtain their consent [<a href="#rid2">2</a>]. The OPO staff will also coordinate evaluation of the donor for suitability for transplant and will communicate with the United Network for Organ Sharing (UNOS) to match the donor with an appropriate recipient from the waiting list. (See  <a class="medical medical_review" href="/d/html/4659.html" rel="external">"Lung transplantation: An overview"</a>.)</p><p class="headingAnchor" id="H3"><span class="h1">DONATION AFTER CIRCULATORY DEATH</span></p><p class="headingAnchor" id="H3024727454"><span class="h2">Definition and epidemiology</span><span class="headingEndMark"> — </span>Most experts prefer "donation after circulatory death" (DCD) or "donation after circulatory determination of death" (DCDD) to "donation after cardiac death" or "nonbeating heart donation (NHBD)." This terminology recognizes and emphasizes that this method of organ donation occurs after cessation of circulatory and respiratory, not cardiac, function [<a href="#rid3">3</a>]. "Controlled donation after circulatory death" (cDCD) can also be found in the literature. There is no official consensus on the terminology.</p><p>DCD has become an accepted method of increasing the donor pool in some transplant centers and organ procurement organizations (OPOs) [<a href="#rid4">4</a>], although the exact definition of circulatory death and the timing of organ procurement remain controversial. These donors can be classified according to the Maastricht system, which was developed in 1995 and revised in 2014 [<a href="#rid5">5,6</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>I Dead on arrival to hospital</p><p class="bulletIndent1"><span class="glyph">●</span>II Unsuccessful resuscitation</p><p class="bulletIndent1"><span class="glyph">●</span>III Awaiting cardiac arrest (inpatient withdrawal of support)</p><p class="bulletIndent1"><span class="glyph">●</span>IV Cardiac arrest while brain-dead</p><p class="bulletIndent1"><span class="glyph">●</span>V Euthanasia/medically assisted cardiocirculatory death</p><p></p><p>Since the first successful transplantation of lungs from a DCD donor in 2001, ethical and legal frameworks have been put in place to investigate and utilize increasing numbers of DCD allografts [<a href="#rid7">7,8</a>]. Up to 20 to 60 percent of all lung transplants come from DCD in Australian and European centers, the majority of which are DCD-III [<a href="#rid9">9</a>]. Small numbers of DCD-V lung transplants have also been permitted in the Netherlands and some provinces of Canada, with equivalent outcomes to DCD-III donation [<a href="#rid10">10-12</a>]. DCD accounts for only a small percentage of deceased organ donors in the United States, with the majority of lung transplant programs having never performed such transplantation. According to the Organ Procurement and Transplant Network annual data report, almost 7 percent of lung transplant recipients received lungs from DCD donors in 2020 [<a href="#rid13">13</a>]. The majority of transplants are from donation after brain death, discussed above. (See <a class="local">'Donation after brain death'</a> above.)</p><p>Situations in which DCD may be considered include irreversible brain injury, end stage musculoskeletal disease, and high spinal cord injury [<a href="#rid14">14,15</a>]. These criteria may be used when the donor does not meet criteria for brain death (see <a class="local">'Donation after brain death'</a> above). Other situations include severe critical illness, sudden death without significant thoracic or abdominal trauma, known time of cardiac arrest, and cardiopulmonary resuscitation maneuvers started within 15 minutes of cardiac arrest [<a href="#rid14">14</a>].</p><p class="headingAnchor" id="H3439618722"><span class="h2">Protocol</span><span class="headingEndMark"> — </span>The details of protocols and management recommendations for DCD have been the subject of consensus conferences followed by practice guidelines [<a href="#rid14">14,16,17</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Decision to withdraw life-sustaining therapies</strong> – The decision to withdraw life-sustaining therapies should only be made by the treating clinician/team and patient family members or proxies. It should not be influenced by the prospect of organ donation. Organ transplant professionals have <strong>no</strong> role and must not be involved in this decision.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antemortem evaluation</strong> – The local OPO staff should become involved immediately after the decision is made to withdraw life-sustaining treatment. The OPO staff will coordinate communication with the United Network for Organ Sharing (UNOS), the transplant team, and the family during the evaluation of the donor's suitability for transplant. (See  <a class="medical medical_review" href="/d/html/4659.html" rel="external">"Lung transplantation: An overview"</a>.)</p><p></p><p class="bulletIndent1">The American Society of Transplant Surgeons recommends a prewithdrawal huddle among the surgical team, OPO personnel, and hospital staff to go over the planned sequence of events, verify the consent documents, confirm the roles of team members, and review hospital policies regarding withdrawal of life-sustaining therapy [<a href="#rid17">17</a>]. </p><p></p><p class="bulletIndent1">Ante mortem interventions are ethically appropriate if they contribute to good transplant outcomes and have a low chance of harming a prospective donor [<a href="#rid8">8</a>]. These may include obtaining blood samples, performance of bronchoscopy, placement of a nasogastric tube to decompress the stomach, injection of heparin to prevent thromboembolism, use of vasodilatory agents to improve organ perfusion, and the placement of arterial and/or venous cannulae for rapid access at the time of death [<a href="#rid8">8</a>]. In the United States, informed consent may be appropriate for medication administration and procedures ante mortem [<a href="#rid17">17</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Timeframe for withdrawal of life-sustaining therapy</strong> – In the setting of withdrawal of life-sustaining treatment, the time limit to circulatory death after treatment withdrawal may be up to two hours and still enable organ recovery. Several studies have developed criteria to help predict the likelihood of circulatory death within 60 to 120 minutes after planned withdrawal of life support, but more research is needed to help optimize timing of withdrawal of life-sustaining treatments and to reliably identify those who will die within two hours after withdrawal, as described separately. (See  <a class="medical medical_review" href="/d/html/114280.html" rel="external">"Evaluation of the potential deceased organ donor (adult)", section on 'Donation after circulatory death'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Declaration of death</strong> – Organ procurement <strong>must </strong>follow irreversible cessation of life; organ retrieval may not cause the death of the donor.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Definition of circulatory death</strong> – Clinical examination that reveals the absence of responsiveness, heart sounds, pulse, and respiratory effort defines circulatory death. Confirmatory tests may be performed in accordance with the hospital protocol demonstrating any of the following criteria to prove absence of circulation [<a href="#rid18">18,19</a>]:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Absence of arterial pulsations observed by an indwelling arterial line</p><p class="bulletIndent3"><span class="glyph">-</span>Absence of opening of the aortic valve by echocardiography</p><p class="bulletIndent3"><span class="glyph">-</span>Absence of circulation by arterial Doppler studies</p><p class="bulletIndent3"><span class="glyph">-</span>Absence electrical activity on an electrocardiogram</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Observation period following circulatory death</strong> – Most OPO and hospital policies require an observation period of five minutes without circulation to confirm the absence of circulation is permanent [<a href="#rid9">9,16</a>], although some continue to follow older guidelines of two to five minutes [<a href="#rid15">15,20</a>]. Observation periods should not exceed five minutes to avoid an unnecessary increase in warm ischemia time [<a href="#rid17">17</a>]. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Special considerations for normothermic regional perfusion (NRP) </strong>– To assist in organ recovery from warm ischemic insult during controlled DCD, some centers are increasingly using abdominal or thoraco-abdominal NRP after the declaration of death [<a href="#rid21">21</a>]. This re-establishment of circulation to the abdomen, heart, and lungs after the declaration of death has raised legal and ethical concerns [<a href="#rid22">22-24</a>]. The International Society for Heart and Lung Transplant (ISHLT) advocates a mandatory five-minute observation period in this setting to rule out autoresuscitation, as well as contingency plans to abort NRP if there are any concerns that death criteria are not satisfied [<a href="#rid9">9</a>].</p><p></p><p class="headingAnchor" id="H911967333"><span class="h1">OUTCOMES BASED ON DONATION TYPE</span><span class="headingEndMark"> — </span>Donation after circulatory death (DCD) and donation after brain death (DBD) have demonstrated similar lung transplantation graft survival in multiple observational cohorts.</p><p class="bulletIndent1"><span class="glyph">●</span>A systematic review and a large international multi-center registry study of lung transplantation outcomes showed no difference in short or long-term survival between DCD and DBD [<a href="#rid25">25,26</a>]. A follow-up multicenter registry study focusing on only the high-risk recipients (patients bridged with extracorporeal membrane oxygenation, patients with idiopathic pulmonary arterial hypertension, and retransplants) also found no difference in long-term survival between DCD and DBD [<a href="#rid27">27</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a six-year single-center study that included 60 transplants from DCD donors, there was a higher incidence of primary graft dysfunction grade 3 and higher risk of bronchiolitis obliterans syndrome (BOS) in the long-term follow-up; however, the overall cumulative survival was not significantly different [<a href="#rid28">28</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A separate study using data from the United Network for Organ Sharing (UNOS) compared graft survival in 479 recipients of lungs from brain-dead donors that had been resuscitated from a cardiac arrest that occurred after declaration of brain death with survival of lung grafts from nonarrest donors [<a href="#rid29">29</a>]. No significant difference was found in perioperative mortality, airway dehiscence, dialysis requirement, postoperative length of stay, or overall survival.</p><p></p><p>Strategies to maintain the integrity of the allograft and reduce ischemic times from the moment of circulatory death to transplantation are key to the success of DCD. A discussion of potential interventions to preserve lung function is presented separately. (See  <a class="medical medical_review" href="/d/html/4652.html" rel="external">"Lung transplantation: Donor lung procurement and preservation"</a>.)</p><p class="headingAnchor" id="H4"><span class="h1">DONOR SELECTION</span><span class="headingEndMark"> — </span>No controlled data exist to determine what constitutes ideal donor candidacy. Consensus and experience have identified some ideal and other less than ideal, or "expanded," donor characteristics that are reviewed here.</p><p>Since the lung donor usually will be donating other organs, coordination between transplant teams is critical to allow recovery of multiple organs at nearly the same time. Further information regarding donor organ preservation is presented separately. (See  <a class="medical medical_review" href="/d/html/4652.html" rel="external">"Lung transplantation: Donor lung procurement and preservation"</a>.)</p><p class="headingAnchor" id="H5"><span class="h2">Size matching</span><span class="headingEndMark"> — </span>Matching of the size of a donor lung with a recipient is usually based on donor and recipient height, although some centers also use estimates of lung volume made from chest radiographs [<a href="#rid30">30,31</a>]. While the optimal degree of fit is unknown and the correlation between donor and recipient size need not be perfect, a close size match is preferred [<a href="#rid32">32</a>]. The underlying disease of the recipient may affect this, since the larger thoracic cavity of an emphysematous patient may be more amenable to a larger donor lung, and a smaller lung may fit well in the thoracic cavity of a patient with pulmonary fibrosis. Additionally, oversized allografts may be better accommodated as a single than bilateral lung transplant because mediastinal shift allows more space for a single allograft in a small thoracic cavity.</p><p>In some cases, donors are ideal matches for recipients in many ways, except for size of the lung. In these cases, one alternative may be to perform a split lung bilateral lobar lung transplant or to downsize a large donor lung by lobectomy or wedge resection [<a href="#rid33">33</a>], although this may lead to poorer outcomes [<a href="#rid34">34</a>]. Additional information on size-matching at the time of procurement and the impact of size-matching on lung transplant outcomes are discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/4652.html" rel="external">"Lung transplantation: Donor lung procurement and preservation", section on 'Donor and recipient size matching'</a>.)</p><p class="headingAnchor" id="H6"><span class="h2">Ideal donor criteria</span><span class="headingEndMark"> — </span>Criteria based on expert opinion and transplant experience have been established for "ideal" donor candidates, although donors meeting all "ideal" donor criteria are uncommon  (<a class="graphic graphic_table graphicRef74075" href="/d/graphic/74075.html" rel="external">table 1</a>) [<a href="#rid35">35,36</a>]. These criteria include: age less than 55 years, clear chest radiograph, arterial oxygen tension/fraction of inspired oxygen (PaO<sub>2</sub>/FiO<sub>2</sub>) &gt;300 mmHg at positive end-expiratory pressure (PEEP) 5, less than 20 pack year smoking history, absence of chest trauma, no evidence of aspiration or sepsis, no prior cardiopulmonary surgery, and absence of purulent secretions or gastric contents on bronchoscopic visualization prior to procuring the lungs. Based on characteristics of accepted and rejected organs from brain-dead donors in the Scientific Registry of Transplant Recipients database (n = 83,219), a lung donor acceptability score has been developed that provides a predicted probability of donor lung acceptance [<a href="#rid37">37</a>]. However, this <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fsites.wustl.edu%2Flundon%2F&amp;token=fS79j%2FZG7ECJ4dswsfa8PzS4ogji7MFXtJieqcWddDqOvGy3W%2BYLXdDSY2xkx%2BzQ&amp;TOPIC_ID=4664" target="_blank">calculator</a> does not predict suitability per se, as low scoring (ie, less acceptable) donor lungs that were nevertheless selected for transplantation demonstrate survival rates comparable with those from higher scoring donors. </p><p>Donors should be excluded if they are infected with SARS-CoV-2, HIV, human T-cell leukemia-lymphoma virus, or have active systemic viral infection (eg, measles, rabies, adenovirus, enterovirus, West Nile, and parvovirus), prion-related disease, or herpetic meningoencephalitis [<a href="#rid38">38,39</a>]. Certain other infections, including lower respiratory tract infections, may also make lung donation less desirable. (See <a class="local">'Donor infection'</a> below.)</p><p>Any donor satisfying ideal inclusion and exclusion criteria should be considered for lung donation.</p><p class="headingAnchor" id="H7"><span class="h2">Expanded donor criteria</span><span class="headingEndMark"> — </span>Most potential organ donors do not meet the ideal lung donor criteria  (<a class="graphic graphic_table graphicRef74075" href="/d/graphic/74075.html" rel="external">table 1</a>) [<a href="#rid35">35</a>], so many lung transplant programs use expanded criteria to increase the donor pool. When an extended criteria donor is being considered, effective communication between the organ procurement organization (OPO) coordinator and the transplant teams is essential. Each transplant team must know the original and current conditions of the donor. While outcomes for less-than-ideal criteria are acceptable, it is still the choice of the surgeon whether to accept a less-than-ideal donor lung. Some retrospective studies have examined outcomes for these expanded donor criteria [<a href="#rid40">40-46</a>].</p><p class="headingAnchor" id="H8"><span class="h3">Advanced donor age</span><span class="headingEndMark"> — </span>Fifty-five years has been regarded as the upper age limit for an "ideal" candidate, based on the belief that accrual of comorbid conditions occurs as age increases [<a href="#rid47">47</a>]. Several studies have examined using lungs from older donors [<a href="#rid42">42,43,48-56</a>].</p><p>Results are mixed, with some indication of increased risk to the recipient, although other risk factors (such as ischemic time) may explain the difference. In a retrospective study of lung transplant recipients from January 2005 to June 2014 from the UNOS thoracic database, lungs from donors aged &gt;60 years were utilized in 4 percent of recipients and were associated with a slightly worse five year (44 percent versus 52 percent, p&lt;0.001) overall survival, although not among recipients older than 50 years [<a href="#rid54">54</a>]. No significant difference in survival was noted between recipients of lungs from young versus old donors when bilateral transplantation was performed.</p><p>Other studies have not shown a significant difference in outcomes when donors up to age 65 have been used [<a href="#rid50">50,51</a>]. A large retrospective analysis of 8860 lung allograft recipients from the Organ Procurement and Transplant Network (UNOS) database in the post lung allocation score (LAS) era (2005 to 2012) revealed no significant increase in one year graft failure among donors aged 55 to 64 compared with donors aged 18 to 54 [<a href="#rid53">53</a>].</p><p>In a single center retrospective study, no significant survival differences were detected when donor lungs ≥70 years were pre-selected for various criteria, including smoking status, oxygenation index, opacities on chest radiographs, and implanted in older recipients without pulmonary hypertension or idiopathic pulmonary fibrosis [<a href="#rid51">51</a>].</p><p class="headingAnchor" id="H9"><span class="h3">ABO compatibility</span><span class="headingEndMark"> — </span>ABO-identical matches are preferred and may lead to a survival advantage over ABO-compatible matches. However, there is reported success using ABO-compatible rather than ABO-identical matches [<a href="#rid57">57-60</a>]. Lung transplant in the setting of ABO incompatibility is not recommended.</p><p>In a retrospective database study, the outcomes of 342 single lung recipients from ABO-compatible donors were compared with those of 3230 single lung transplant recipients from ABO identical donors [<a href="#rid60">60</a>]. Lungs from ABO-compatible donors were not associated with increased mortality (hazard ratio, 1.02, 95% CI 0.8-1.22). The two groups did not differ significantly in median length of stay, incidence of post-transplant airway dehiscence, or number of acute rejection episodes. While this study is reassuring regarding the use of ABO-compatible donors when ABO-identical matches are not available, further study is needed to determine the optimal immunosuppression in this setting and to clarify long-term outcomes.</p><p>A potential concern related to use of ABO-compatible lungs is the passenger leukocyte syndrome, in which donor B lymphocytes carried in the lung allograft release antibodies that react with recipient red blood cells, causing acute hemolysis [<a href="#rid61">61,62</a>]. The occurrence of the passenger leukocyte syndrome and post-transplant hemolysis could not be determined in the retrospective study described above [<a href="#rid60">60</a>]. (See  <a class="medical medical_review" href="/d/html/7330.html" rel="external">"Anemia and the kidney transplant recipient", section on 'Later (&gt;3 months) posttransplantation'</a>.)</p><p class="headingAnchor" id="H10"><span class="h3">Abnormal chest radiograph</span><span class="headingEndMark"> — </span>Patients with abnormalities on the chest radiograph should not be automatically rejected from donation [<a href="#rid35">35</a>]. If the lesion is unilateral, the unaffected lung may be used for transplant. Opacities on the chest radiograph should prompt early bronchoscopy to address the character and volume of secretions. Ventilator recruitment maneuvers may clear areas of atelectasis (see  <a class="medical medical_review" href="/d/html/6970.html" rel="external">"Strategies to reduce postoperative pulmonary complications in adults", section on 'Lung expansion'</a>). The combination of opacities on chest radiograph and purulent sputum on bronchoscopy was associated with a lower early survival in the transplant recipients in one series [<a href="#rid43">43</a>].</p><p class="headingAnchor" id="H11"><span class="h3">Low PaO2</span><span class="headingEndMark"> — </span>Several reports have examined using donors who do not start with an ideal PaO<sub>2</sub> (PaO<sub>2</sub> &gt;300 mmHg on FiO<sub>2</sub> = 1.0, PEEP = 5 cm H<sub>2</sub>O) [<a href="#rid40">40,43,49,63</a>]. While there are isolated reports of graft failure in this setting, others have reported no increased risk to the recipient [<a href="#rid43">43,44,63</a>]. If the PaO<sub>2</sub> starts below goal, aggressive recruitment strategies should be used to increase the number of functional lung units (see  <a class="medical medical_review" href="/d/html/4401.html" rel="external">"Overview of the management of postoperative pulmonary complications"</a>). The same criteria should be applied at the end of the recruitment maneuver, and there must be evidence for a sustained benefit before the lungs are offered for donation.</p><p>Ex vivo lung perfusion techniques may be an acceptable method to salvage lungs that do not meet ideal PaO<sub>2</sub> criteria due to pulmonary edema, thromboemboli, or contusions. (See <a class="local">'Ex vivo lung perfusion'</a> below and  <a class="medical medical_review" href="/d/html/4652.html" rel="external">"Lung transplantation: Donor lung procurement and preservation", section on 'Normothermic ex-vivo perfusion (after cold static preservation)'</a>.)</p><p class="headingAnchor" id="H103242891"><span class="h3">Diabetes mellitus</span><span class="headingEndMark"> — </span>In a retrospective series of 10,333 lung transplantations performed in the United States, a donor history of diabetes was associated with an increase in mortality [<a href="#rid44">44</a>]. Diabetes has not traditionally been a criterion for donor lung exclusion, so further study of this potential risk factor for decreased lung transplant recipient survival is needed.</p><p class="headingAnchor" id="H12"><span class="h3">Smoking</span><span class="headingEndMark"> — </span>The two main concerns for transplantation of lungs from a donor with a substantial smoking history are the potential for adverse effects on post-transplant lung function/survival and the transmission of cancer that is not evident on chest radiograph [<a href="#rid44">44,47,64-69</a>].</p><p>Generally, moderate to severe COPD or emphysema is apparent by history, oxygenation, ventilator mechanics, chest radiograph, or some combination of these. However, clinically inapparent effects of smoking may affect post-transplant survival.</p><p class="bulletIndent1"><span class="glyph">●</span>In a retrospective study of 510 transplant recipients who received lungs from donors with a smoking history compared with 712 recipients from nonsmoking donors, the three-year mortality was greater in those who received lungs from donors with a positive smoking history (adjusted HR 1.36, 95% CI, 1.11–1.67) [<a href="#rid66">66</a>]. The groups did not differ in baseline age or arterial blood oxygen tension. In addition, recipients of lungs from donors who had smoked had longer stays in the hospital and intensive care units than did those who received lungs from nonsmokers. On the other hand, receiving transplanted lungs from a donor with a smoking history is associated with a lower unadjusted hazard of death than remaining on the waiting list without a transplant (0.79, 95% CI 0.70-0.91).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a retrospective analysis of UNOS database from 2005 to 2011, use of lungs from heavy-smoking donors (HSDs; &gt;20 pack-years) was not associated with increased mortality for single lung transplants (n=498), if the donor was not actively smoking (HR 0.84; 95% CI 0.59-1.19) [<a href="#rid67">67</a>] and double lung transplants (n=766), irrespective of whether the heavy smoking was current or former for the double lung cohort (HR 1.003; 95% CI, 0.867-1.161) [<a href="#rid68">68</a>]. Recipients with HSDs had longer median length of stay (23.0 versus 20.5 days, p = 0.001) for single lung transplant and (18.0 versus 17.0 days, p &lt;0.001) for double lung transplant; and lower peak FEV<sub>1</sub> after single-lung transplantation (80.1 versus 73.4 percent, p = 0.001), but similar peak FEV<sub>1</sub> after double lung transplantation [<a href="#rid67">67,68</a>].</p><p></p><p>While there are case reports of bronchogenic carcinoma of donor origin in the transplanted lung, these are rare, and the donors had substantial smoking histories [<a href="#rid47">47,64</a>]. If the donor lungs are otherwise acceptable, increasing the donor pack-year limit will likely not increase the chances of a poor recipient outcome [<a href="#rid44">44,65</a>].</p><p class="headingAnchor" id="H13"><span class="h3">Malignancy</span><span class="headingEndMark"> — </span>With a few exceptions a history of malignancy is an absolute contraindication to organ donation [<a href="#rid35">35</a>]. Low-grade skin cancer (not melanoma), carcinoma-in-situ (for example, of the cervix), and prostate cancer &lt;Gleason 6 have an exceedingly low potential for metastasis and thus should not be exclusionary factors. Active (acute or chronic) leukemia, lymphoma, and plasmacytoma are unacceptable risks for organ donation. A history of melanoma is considered an absolute contraindication for organ donation [<a href="#rid35">35</a>].</p><p>Primary central nervous system (CNS) tumors are unlikely to have spread past the blood-brain barrier. However, high-grade tumors, particularly glioblastomas or medulloblastomas, are at increased risk of metastasis and may represent contraindications to transplant. Craniotomy, ventricular shunts, and radiation to the tumor also increase the chance of tumor spread [<a href="#rid70">70</a>].</p><p>Oncologist consultation is encouraged when there is uncertain transmission risk in the setting of malignancy (history or active). Informed consent should be obtained from the recipient prior to implantation.</p><p class="headingAnchor" id="H14"><span class="h3">Donor infection</span><span class="headingEndMark"> — </span>Transmission of infection from the donor to the lung transplant recipient is a significant risk for the recipient  (<a class="graphic graphic_table graphicRef76293" href="/d/graphic/76293.html" rel="external">table 2</a>) [<a href="#rid38">38,71,72</a>]. Certain donor infections do not limit transplant, provided the donor and recipient receive adequate treatment. In general, there is insufficient evidence to suggest that adequately treated donor infection with gram-positive or gram-negative pathogens affect outcomes; however, concern remains for infections including bacteremia or pneumonia with multidrug-resistant organisms. Invasive fungal disease is a contraindication.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bacterial and mycobacterial infections</strong> – Bacterial infections are the most problematic in the immediate postoperative period. Most centers administer empiric antibiotics to the recipient at the time of transplant and adjust these once results of intraoperative donor tracheal or bronchial aspirates are available [<a href="#rid38">38</a>]. In a retrospective case series, recipients of lungs that had potentially pathogenic bacteria cultured at the time of procurement spent significantly longer time on mechanical ventilation but without effect on 30 day mortality [<a href="#rid73">73</a>]. </p><p></p><p class="bulletIndent1">Organs from bacteremic donors generally result in few if any transmitted infections when the donor has received pathogen-specific antibiotics for a minimum of 48 hours before procurement [<a href="#rid35">35</a>].</p><p></p><p class="bulletIndent1">Chest radiographs of potential donors should be screened for any evidence of active or prior <em>Mycobacterial tuberculosis </em>infection, which would exclude the patient as a transplant donor. Although transmission of <em>M tuberculosis</em> from donors has been reported in the absence of chest radiograph findings, more extensive testing for <em>M tuberculosis</em> is not feasible as it would delay organ procurement [<a href="#rid74">74</a>].</p><p></p><p class="bulletIndent1">Active parasitic disease in the donor is a contraindication for the use of organs [<a href="#rid75">75</a>]. Donor derived transmission of <em>Trypanosoma cruzi </em>and <em>Strongyloides stercoralis</em> were reported, and targeted screening of donors coming from or with travel history to endemic areas by serologic testing is recommended [<a href="#rid76">76</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>HIV, hepatitis C, hepatitis B</strong> – Transplant professionals and patients need to recognize that even comprehensive donor screening cannot detect all transmissible infections. Potential donors are screened for hepatitis C, hepatitis B surface antigen, hepatitis B core antibody positivity, and HIV. In addition to serologic testing, Nucleic Acid Amplification Testing (NAT) is used for HIV, hepatitis C virus (HCV), and hepatitis B virus (HBV) to determine the viral load. The risk of HIV, HCV, or HBV transmission from a NAT negative donor organ is low (around 1 percent or less) [<a href="#rid77">77</a>]. (See  <a class="medical medical_review" href="/d/html/1396.html" rel="external">"Infection in the solid organ transplant recipient", section on 'HIV, HTLV, and hepatitis viruses'</a>.)</p><p></p><p class="bulletIndent1">Directly acting antiviral agents (DAA) have demonstrated high cure rates for HCV in transplant recipients and the nonimmunosuppressed general population alike, raising the possibility that DAA might enable use of lungs from HCV-positive donors. In an observational study, pre-emptive DAA therapy (<a class="drug drug_general" data-topicid="108951" href="/d/drug information/108951.html" rel="external">sofosbuvir-velpatasvir</a>), administered for the first four weeks after transplantation, prevented development of HCV infection in 36 HCV-uninfected recipients who received lungs from HCV-positive donors [<a href="#rid78">78</a>]. While promising, this was a small study with short-term follow-up. In view of the high cure rates with new antiviral treatments, donors with hepatitis C ELISA positivity but NAT negative should no longer be excluded without discussion with the recipient. Even donors with true hepatitis C infection can be transplanted into a recipient who is hepatitis C positive [<a href="#rid38">38</a>]. (See  <a class="medical medical_review" href="/d/html/1396.html" rel="external">"Infection in the solid organ transplant recipient", section on 'HIV, HTLV, and hepatitis viruses'</a> and  <a class="medical medical_review" href="/d/html/7361.html" rel="external">"Hepatitis C virus infection in kidney donors"</a>.)</p><p></p><p class="bulletIndent1">A donor with active HBV, defined as positive HBV surface antigen (HBsAg) and/or detectable HBV NAT is expected to transmit the infection. Lung transplantation from donors with active HBV is seldom considered in nonendemic regions due to limited outcome data. Of the 271,593 organ transplants performed in the United States between January, 2009 and December, 2017, there were 25 events of donor-derived HBV transmission reported to UNOS; only one lung recipient seroconverted at 12 months [<a href="#rid79">79</a>]. The risk of HBV transmission to the lung recipient is low in the setting of hepatitis B core (HBc) antibody positivity alone with an undetectable viral load [<a href="#rid80">80,81</a>]. Potential causes of HBcAb positive, but nucleic acid test (NAT) negative, HBsAg negative, and HBsAb negative panel include (1) resolved infection, (2) false positive anti-HBc Ab, (3) occult chronic infection, or (4) resolving acute infection. For susceptible recipients (HBcAb negative, HBsAb negative) of lungs from donors with these results, antiviral prophylaxis for up to one year may be considered, although data are limited [<a href="#rid80">80,82</a>].</p><p></p><p class="bulletIndent1">Lung recipients with adequate postvaccination HBsAb titers are at very low risk of HBV transmission and only require post-transplant monitoring if they receive lungs from an HBcAb positive donor. There are case reports of emergency transplantation from HBsAg positive donors with variable levels of serum HBV DNA to susceptible (HBsAg and HBcAb negative) recipients. <a class="drug drug_general" data-topicid="8816" href="/d/drug information/8816.html" rel="external">Entecavir</a> and HBIG were started immediately with excellent short-term clinical outcomes [<a href="#rid83">83</a>].</p><p></p><p class="bulletIndent1">Individuals who are seronegative for HIV but meet high-risk behavioral criteria for HIV infection should not be excluded as organ donors, but the transplant team and potential recipient should be notified [<a href="#rid35">35</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cytomegalovirus (CMV)</strong> – Although the presence of antibodies to cytomegalovirus was associated with increased mortality in a retrospective study of 10,333 lung transplants, this has not traditionally been considered an exclusionary donor criterion [<a href="#rid44">44</a>].</p><p></p><p class="bulletIndent1">Routine prophylaxis against CMV infection has reduced the morbidity and mortality associated with CMV infection. While it is preferable to avoid transplanting lungs from CMV positive donors into CMV negative recipients, it is not always possible. Any donor or recipient with CMV positivity requires close monitoring in addition to CMV prophylaxis. (See  <a class="medical medical_review" href="/d/html/8313.html" rel="external">"Prevention of cytomegalovirus infection in lung transplant recipients"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other viruses</strong> – Parvovirus B19 transmission has led to red cell aplasia in the recipient, but this was treatable with intravenous immunoglobulin [<a href="#rid38">38</a>]. Donors with human herpes viruses 6-8, nonpulmonary herpes simplex, and varicella may be used with caution. (See  <a class="medical medical_review" href="/d/html/13952.html" rel="external">"Viral infections following lung transplantation", section on 'Herpes viruses'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>West Nile virus</strong> – West Nile virus is a mosquito-borne virus that is endemic to most of the United States. Serology is prolonged beyond the period of transmission risk and the NAT is only transiently positive with reports of transmission in NAT-negative donors. Lungs from donors with unexplained active meningitis, encephalitis, or flaccid paralysis from regions with WNV activity should be declined. NAT and IgM testing can be performed after donation in circumstances of high clinical suspicion for WNV disease [<a href="#rid76">76</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Zika virus</strong> – No reports of confirmed cases of donor transmitted Zika virus infection exist to date, although Zika virus has been detected in a number of tissues and body fluids, raising the concern for transmission via transplantation. Diagnostics remain challenging and are available primarily in central reference laboratories. Current guidelines advise that donors with positive NAT test or clinical symptoms compatible with Zika should be excluded for 28 days from the positive test or the onset of symptoms. [<a href="#rid84">84,85</a>].</p><p></p><p class="bulletIndent1">Concern for Zika or other emerging or endemic viral infections should not summarily exclude donors from transplantation; rather, the risk of donor derived infection should be balanced with the benefits of transplantation in each potential recipient. Consider consulting a transplant infectious disease expert for donors with symptoms, recent travel history, or other epidemiologic risk factors.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Respiratory viruses</strong> – In general, lung donation from patients with respiratory viral infection (eg, influenza, parainfluenza, respiratory syncytial virus, adenovirus) of the lower respiratory tract is avoided. Screening of donors for most respiratory viruses (other than coronavirus disease 2019 [COVID-19]) with PCR or cross-sectional imaging is only recommended if there is clinical concern based on symptoms [<a href="#rid75">75</a>]. Guidelines advise declining lung donation from donors with imaging evidence of viral pneumonia [<a href="#rid86">86</a>]. Respiratory viral infection other than COVID-19 does not typically preclude transplantation of solid organs other than the lung.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>COVID-19</strong> – The virology, clinical manifestations, diagnosis, and management of COVID-19 are described separately. (See  <a class="medical medical_review" href="/d/html/126981.html" rel="external">"COVID-19: Epidemiology, virology, and prevention"</a> and  <a class="medical medical_review" href="/d/html/128404.html" rel="external">"COVID-19: Diagnosis"</a> and  <a class="medical medical_review" href="/d/html/127429.html" rel="external">"COVID-19: Management in hospitalized adults"</a> and  <a class="medical medical_review" href="/d/html/127419.html" rel="external">"COVID-19: Management of the intubated adult"</a>.)</p><p></p><p class="bulletIndent1">Transmission of SARS-CoV-2 via a lung allograft has been reported from donors who initially tested negative by nasal swab but were later confirmed positive on a lower respiratory tract sample [<a href="#rid87">87,88</a>]. In response, the Organ Procurement and Transplantation Network (OPTN) has mandated that all potential lung donors undergo testing of a lower respiratory tract specimen (eg, tracheal aspirate, bronchoscopic washing, or bronchoalveolar lavage) for SARS-CoV-2 by nucleic acid test (NAT) in addition to screening by symptoms, exposures, and upper respiratory tract sampling [<a href="#rid89">89</a>]. The accuracy of NAAT is discussed in greater detail separately. (See  <a class="medical medical_review" href="/d/html/128404.html" rel="external">"COVID-19: Diagnosis", section on 'NAAT (including RT-PCR)'</a>.)</p><p></p><p class="bulletIndent1">As SARS-CoV-2 infection has the potential to cause pneumonia, diffuse alveolar damage, alveolar hemorrhage, and death in lung-transplant recipients, deceased donors with known or suspected COVID-19 within the past 21 days, a positive NAT for SARS-CoV-2, or a high likelihood of SARS-CoV-2 infection based on symptoms or imaging should not be used for lung transplantation [<a href="#rid86">86</a>]. Caution is advisable for potential donors with known contact with a confirmed or suspected case, travel to or residence in an area of high risk of transmission within 14 days, or symptoms of fever, influenza-like illness, or pneumonia regardless of exposure within the past 14 days. However, the risk of disease transmission and its possible adverse impact on the outcome of transplantation should be weighed against the risk of death for the potential recipient if that opportunity for transplantation is missed [<a href="#rid90">90</a>]. The general screening of potential organ donors for SARS-CoV-2 is described separately. (See  <a class="medical medical_review" href="/d/html/127582.html" rel="external">"COVID-19: Issues related to solid organ transplantation"</a>.)</p><p></p><p class="bulletIndent1">Potential donors with a positive COVID test more than 21 days prior to organ harvest, negative lower respiratory tract PCR, lack of hypercoagulability or hyperinflammatory syndrome during the terminal hospitalization, and negative imaging for viral pneumonia may be appropriate candidates for thoracic organ donation [<a href="#rid91">91</a>], although experience with lung transplantation under these conditions is very limited.</p><p></p><p class="headingAnchor" id="H15"><span class="h2">Ex vivo lung perfusion</span><span class="headingEndMark"> — </span>Complications such as pulmonary edema, contusions, and vascular thrombosis have typically rendered donor lungs unacceptable for transplantation, thereby reducing the supply of donor lungs. Efforts to improve the quality, and therefore the quantity, of lungs available for transplantation are ongoing. Ex vivo lung perfusion (EVLP, also known as ex vivo reconditioning) is being explored as a way to increase the number of acceptable lungs and is described separately. (See  <a class="medical medical_review" href="/d/html/4652.html" rel="external">"Lung transplantation: Donor lung procurement and preservation", section on 'Normothermic ex-vivo perfusion (after cold static preservation)'</a>.)</p><p class="headingAnchor" id="H3042848739"><span class="h2">Future directions</span></p><p class="headingAnchor" id="H745459878"><span class="h3">Donor genetics</span><span class="headingEndMark"> — </span>Gene expression microarray technology has been used to find molecular markers that predict primary graft dysfunction (PGD) in transplant recipients. In a case-control study, gene microarrays of 10 donor lungs that developed PGD were compared with 16 controls with a favorable outcome; four upregulated genes, ATP11B, FGFR2, EGLN1, and MCPH1, were associated with development of PGD [<a href="#rid92">92</a>]. Such biologic signatures may in the future supplement clinical criteria used at the preimplantation evaluation and selection stage to predict post-transplant complications, such as primary graft dysfunction, and help guide therapy in the immediate post-transplant period.</p><p>Gene therapy is also being investigated as a potential strategy to increase the number of donor lungs. Injured human lungs that were considered to be unsuitable for clinical use were treated with adenoviral mediated human interleukin (IL)-10 gene therapy. After preservation ex-vivo at body temperature, the IL-10 treated lungs showed reduced markers of inflammation and improved function (PaO<sub>2</sub> and pulmonary vascular resistance) compared with control untreated lungs [<a href="#rid93">93</a>].</p><p class="headingAnchor" id="H554829713"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/122278.html" rel="external">"Society guideline links: Lung transplantation"</a>.)</p><p class="headingAnchor" id="H23"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Donation types</strong> – The majority of transplanted lungs are donated after brain death (DBD), although a small portion are donated after circulatory death (DCD). Donation after circulatory death follows detailed protocols to ensure circulatory death prior to procurement and to increase the chances of successful organ recovery. (See <a class="local">'Donation after brain death'</a> above and <a class="local">'Donation after circulatory death'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Outcomes based on donation type</strong> – As experience with lung DCD increases, observational studies show equivalent long-term outcomes compared with those of donation after brain death. (See <a class="local">'Outcomes based on donation type'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ideal donor criteria</strong> – Ideal donors for lung transplant are less than 55 years of age, have smoked less than 20 pack years, have a normal chest radiograph, near normal gas exchange, and absence of chest trauma, prior cardiothoracic surgery, known aspiration, sepsis, or purulent respiratory secretions. (See <a class="local">'Ideal donor criteria'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Use of organs from donors not meeting ideal donor criteria</strong> – Several retrospective series have examined recipient outcomes after use of donor lungs that do not meet ideal donor criteria and have found that outcomes for "expanded" donor criteria are only slightly worse than those for "ideal" organs. (See <a class="local">'Expanded donor criteria'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Mildly impaired lung function</strong> – When donor lungs are less than ideal (eg, PaO<sub>2</sub>:FiO<sub>2</sub> &lt;300 mmHg, radiographic pulmonary edema), recruitment maneuvers and/or several hours of normothermic ex vivo lung perfusion (EVLP) may allow functional recovery and safe use of these lungs. (See <a class="local">'Abnormal chest radiograph'</a> above and <a class="local">'Low PaO2'</a> above and <a class="local">'Ex vivo lung perfusion'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Donors with a heavy smoking history</strong> – The main concern about using lungs from donors who have a tobacco smoking history of greater than 20 pack years is the possibility of transmission of bronchogenic cancer to the recipient. Usually, significant chronic obstructive pulmonary disease (COPD) can be detected by a history of respiratory symptoms, abnormality of chest imaging, and abnormal ventilator mechanics. (See <a class="local">'Smoking'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Malignancy</strong> – Malignancy is generally an absolute contraindication for organ donation, unless an adequate disease-free interval has elapsed or the malignancy is of extremely low potential for metastasis (eg, carcinoma in situ of the cervix or some low grade nonmelanoma skin cancers). (See <a class="local">'Malignancy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Infection</strong> – Transmission of infection from the donor to the lung transplant recipient is a significant risk for the recipient; infections that exclude an individual from being an organ donor or require specific intervention are listed in the table  (<a class="graphic graphic_table graphicRef76293" href="/d/graphic/76293.html" rel="external">table 2</a>). (See <a class="local">'Donor infection'</a> above.)</p><p></p><p class="headingAnchor" id="H9711125"><span class="h1">ACKNOWLEDGMENTS</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Pamela McShane, MD, and Edward Garrity, MD, MBA, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Wijdicks EF. The diagnosis of brain death. N Engl J Med 2001; 344:1215.</a></li><li class="breakAll">Medicare and Medicaid Programs; Conditions for Coverage for Organ Procurement Organizations (OPOs); Final Rule. Services, DoHaH (Ed), Federal Register May 31, 2006.</li><li><a class="nounderline abstract_t">Bernat JL, Capron AM, Bleck TP, et al. The circulatory-respiratory determination of death in organ donation. Crit Care Med 2010; 38:963.</a></li><li><a class="nounderline abstract_t">Hirji SA, Halpern AL, Helmkamp LJ, et al. Geographic and temporal patterns of growth in the utilization of donation after circulatory death donors for lung transplantation in the United States. J Heart Lung Transplant 2020; 39:1313.</a></li><li><a class="nounderline abstract_t">Kootstra G. Statement on non-heart-beating donor programs. Transplant Proc 1995; 27:2965.</a></li><li><a class="nounderline abstract_t">Evrard P, Belgian Working Group on DCD National Protocol. Belgian modified classification of Maastricht for donors after circulatory death. Transplant Proc 2014; 46:3138.</a></li><li><a class="nounderline abstract_t">Steen S, Sjöberg T, Pierre L, et al. Transplantation of lungs from a non-heart-beating donor. Lancet 2001; 357:825.</a></li><li><a class="nounderline abstract_t">Gries CJ, White DB, Truog RD, et al. An official American Thoracic Society/International Society for Heart and Lung Transplantation/Society of Critical Care Medicine/Association of Organ and Procurement Organizations/United Network of Organ Sharing Statement: ethical and policy considerations in organ donation after circulatory determination of death. Am J Respir Crit Care Med 2013; 188:103.</a></li><li><a class="nounderline abstract_t">Holm AM, Courtwright A, Olland A, et al. ISHLT position paper on thoracic organ transplantation in controlled donation after circulatory determination of death (cDCD). J Heart Lung Transplant 2022; 41:671.</a></li><li><a class="nounderline abstract_t">Ceulemans LJ, Vanluyten C, Monbaliu D, et al. Lung transplant outcome following donation after euthanasia. J Heart Lung Transplant 2022; 41:745.</a></li><li><a class="nounderline abstract_t">Downar J, Shemie SD, Gillrie C, et al. Deceased organ and tissue donation after medical assistance in dying and other conscious and competent donors: guidance for policy. CMAJ 2019; 191:E604.</a></li><li><a class="nounderline abstract_t">Watanabe T, Kawashima M, Kohno M, et al. Outcomes of lung transplantation from organ donation after medical assistance in dying: First North American experience. Am J Transplant 2022; 22:1637.</a></li><li><a class="nounderline abstract_t">Valapour M, Lehr CJ, Skeans MA, et al. OPTN/SRTR 2020 Annual Data Report: Lung. Am J Transplant 2022; 22 Suppl 2:438.</a></li><li><a class="nounderline abstract_t">Bernat JL, D'Alessandro AM, Port FK, et al. Report of a National Conference on Donation after cardiac death. Am J Transplant 2006; 6:281.</a></li><li><a class="nounderline abstract_t">Ethics Committee, American College of Critical Care Medicine, Society of Critical Care Medicine. Recommendations for nonheartbeating organ donation. A position paper by the Ethics Committee, American College of Critical Care Medicine, Society of Critical Care Medicine. Crit Care Med 2001; 29:1826.</a></li><li><a class="nounderline abstract_t">Domínguez-Gil B, Ascher N, Capron AM, et al. Expanding controlled donation after the circulatory determination of death: statement from an international collaborative. Intensive Care Med 2021; 47:265.</a></li><li><a class="nounderline abstract_t">Croome KP, Barbas AS, Whitson B, et al. American Society of Transplant Surgeons recommendations on best practices in donation after circulatory death organ procurement. Am J Transplant 2023; 23:171.</a></li><li><a class="nounderline abstract_t">Guidelines for the determination of death. Report of the medical consultants on the diagnosis of death to the President's Commission for the Study of Ethical Problems in Medicine and Biomedical and Behavioral Research. JAMA 1981; 246:2184.</a></li><li><a class="nounderline abstract_t">Robertson JA. The dead donor rule. Hastings Cent Rep 1999; 29:6.</a></li><li><a class="nounderline abstract_t">Reich DJ, Mulligan DC, Abt PL, et al. ASTS recommended practice guidelines for controlled donation after cardiac death organ procurement and transplantation. Am J Transplant 2009; 9:2004.</a></li><li><a class="nounderline abstract_t">Hoffman JRH, McMaster WG, Rali AS, et al. Early US experience with cardiac donation after circulatory death (DCD) using normothermic regional perfusion. J Heart Lung Transplant 2021; 40:1408.</a></li><li><a class="nounderline abstract_t">Parent B, Caplan A, Moazami N, Montgomery RA. Response to American College of Physician's statement on the ethics of transplant after normothermic regional perfusion. Am J Transplant 2022; 22:1307.</a></li><li><a class="nounderline abstract_t">Adams BL, Brenner L, Levan M, Parent B. cDCDD-NRP is consistent with US legal standards for determining death. Am J Transplant 2022; 22:2302.</a></li><li><a class="nounderline abstract_t">DeCamp M, Prager K, American College of Physicians Ethics, Professionalism and Human Rights Committee. Standards and Ethics Issues in the Determination of Death: A Position Paper From the American College of Physicians. Ann Intern Med 2023; 176:1245.</a></li><li><a class="nounderline abstract_t">Krutsinger D, Reed RM, Blevins A, et al. Lung transplantation from donation after cardiocirculatory death: a systematic review and meta-analysis. J Heart Lung Transplant 2015; 34:675.</a></li><li><a class="nounderline abstract_t">Cypel M, Levvey B, Van Raemdonck D, et al. International Society for Heart and Lung Transplantation Donation After Circulatory Death Registry Report. J Heart Lung Transplant 2015; 34:1278.</a></li><li><a class="nounderline abstract_t">Dos Santos PAR, Teixeira PJZ, Neto DMM, et al. Donation after circulatory death donors in high-risk recipients undergoing bilateral lung transplantation: An ISHLT database registry analysis. J Heart Lung Transplant 2022; 41:712.</a></li><li><a class="nounderline abstract_t">Sabashnikov A, Patil NP, Popov AF, et al. Long-term results after lung transplantation using organs from circulatory death donors: a propensity score-matched analysis†. Eur J Cardiothorac Surg 2016; 49:46.</a></li><li><a class="nounderline abstract_t">Castleberry AW, Worni M, Osho AA, et al. Use of lung allografts from brain-dead donors after cardiopulmonary arrest and resuscitation. Am J Respir Crit Care Med 2013; 188:466.</a></li><li><a class="nounderline abstract_t">Eberlein M, Permutt S, Chahla MF, et al. Lung size mismatch in bilateral lung transplantation is associated with allograft function and bronchiolitis obliterans syndrome. Chest 2012; 141:451.</a></li><li><a class="nounderline abstract_t">Eberlein M, Reed RM, Permutt S, et al. Parameters of donor-recipient size mismatch and survival after bilateral lung transplantation. J Heart Lung Transplant 2012; 31:1207.</a></li><li><a class="nounderline abstract_t">Mason DP, Batizy LH, Wu J, et al. Matching donor to recipient in lung transplantation: How much does size matter? J Thorac Cardiovasc Surg 2009; 137:1234.</a></li><li><a class="nounderline abstract_t">Shigemura N, Bermudez C, Hattler BG, et al. Impact of graft volume reduction for oversized grafts after lung transplantation on outcome in recipients with end-stage restrictive pulmonary diseases. J Heart Lung Transplant 2009; 28:130.</a></li><li><a class="nounderline abstract_t">Montoya P, Bello I, Ascanio F, et al. Graft reduction surgery is associated with poorer outcome after lung transplantation: a single-centre propensity score-matched analysis. Eur J Cardiothorac Surg 2021; 60:1308.</a></li><li><a class="nounderline abstract_t">Kotloff RM, Blosser S, Fulda GJ, et al. Management of the Potential Organ Donor in the ICU: Society of Critical Care Medicine/American College of Chest Physicians/Association of Organ Procurement Organizations Consensus Statement. Crit Care Med 2015; 43:1291.</a></li><li><a class="nounderline abstract_t">Chaney J, Suzuki Y, Cantu E 3rd, van Berkel V. Lung donor selection criteria. J Thorac Dis 2014; 6:1032.</a></li><li><a class="nounderline abstract_t">Heiden BT, Yang Z, Bai YZ, et al. Development and validation of the lung donor (LUNDON) acceptability score for pulmonary transplantation. Am J Transplant 2023; 23:540.</a></li><li><a class="nounderline abstract_t">Garrity ER Jr, Boettcher H, Gabbay E. Donor infection: an opinion on lung donor utilization. J Heart Lung Transplant 2005; 24:791.</a></li><li><a class="nounderline abstract_t">Rosendale JD, Chabalewski FL, McBride MA, et al. Increased transplanted organs from the use of a standardized donor management protocol. Am J Transplant 2002; 2:761.</a></li><li><a class="nounderline abstract_t">Whiting D, Banerji A, Ross D, et al. Liberalization of donor criteria in lung transplantation. Am Surg 2003; 69:909.</a></li><li><a class="nounderline abstract_t">D'Armini AM, Boffini M, Zanotti G, et al. "Twinning procedure" in lung transplantation: influence of graft ischemia on survival and incidence of complications. Transplant Proc 2004; 36:654.</a></li><li><a class="nounderline abstract_t">Aigner C, Winkler G, Jaksch P, et al. Extended donor criteria for lung transplantation--a clinical reality. Eur J Cardiothorac Surg 2005; 27:757.</a></li><li><a class="nounderline abstract_t">Lardinois D, Banysch M, Korom S, et al. Extended donor lungs: eleven years experience in a consecutive series. Eur J Cardiothorac Surg 2005; 27:762.</a></li><li><a class="nounderline abstract_t">Reyes KG, Mason DP, Thuita L, et al. Guidelines for donor lung selection: time for revision? Ann Thorac Surg 2010; 89:1756.</a></li><li><a class="nounderline abstract_t">Sommer W, Kühn C, Tudorache I, et al. Extended criteria donor lungs and clinical outcome: results of an alternative allocation algorithm. J Heart Lung Transplant 2013; 32:1065.</a></li><li><a class="nounderline abstract_t">Mulligan MJ, Sanchez PG, Evans CF, et al. The use of extended criteria donors decreases one-year survival in high-risk lung recipients: A review of the United Network of Organ Sharing Database. J Thorac Cardiovasc Surg 2016; 152:891.</a></li><li><a class="nounderline abstract_t">Orens JB, Boehler A, de Perrot M, et al. A review of lung transplant donor acceptability criteria. J Heart Lung Transplant 2003; 22:1183.</a></li><li><a class="nounderline abstract_t">Bhorade SM, Vigneswaran W, McCabe MA, Garrity ER. Liberalization of donor criteria may expand the donor pool without adverse consequence in lung transplantation. J Heart Lung Transplant 2000; 19:1199.</a></li><li><a class="nounderline abstract_t">Pierre AF, Sekine Y, Hutcheon MA, et al. Marginal donor lungs: a reassessment. J Thorac Cardiovasc Surg 2002; 123:421.</a></li><li><a class="nounderline abstract_t">Bittle GJ, Sanchez PG, Kon ZN, et al. The use of lung donors older than 55 years: a review of the United Network of Organ Sharing database. J Heart Lung Transplant 2013; 32:760.</a></li><li><a class="nounderline abstract_t">Sommer W, Ius F, Salman J, et al. Survival and spirometry outcomes after lung transplantation from donors aged 70 years and older. J Heart Lung Transplant 2015; 34:1325.</a></li><li><a class="nounderline abstract_t">Hayes D Jr, Black SM, Tobias JD, et al. Influence of donor and recipient age in lung transplantation. J Heart Lung Transplant 2015; 34:43.</a></li><li><a class="nounderline abstract_t">Baldwin MR, Peterson ER, Easthausen I, et al. Donor age and early graft failure after lung transplantation: a cohort study. Am J Transplant 2013; 13:2685.</a></li><li><a class="nounderline abstract_t">Whited WM, Henley P, Schumer EM, et al. Does Donor Age and Double Versus Single Lung Transplant Affect Survival of Young Recipients? Ann Thorac Surg 2018; 105:235.</a></li><li><a class="nounderline abstract_t">Hall DJ, Jeng EI, Gregg JA, et al. The Impact of Donor and Recipient Age: Older Lung Transplant Recipients Do Not Require Younger Lungs. Ann Thorac Surg 2019; 107:868.</a></li><li><a class="nounderline abstract_t">Choi AY, Jawitz OK, Raman V, et al. Predictors of Older Donor Lung Use: Are We Too Good at Saying No? Ann Thorac Surg 2020; 110:1683.</a></li><li><a class="nounderline abstract_t">Salerno CT, Burdine J, Perry EH, et al. Donor-derived antibodies and hemolysis after ABO-compatible but nonidentical heart-lung and lung transplantation. Transplantation 1998; 65:261.</a></li><li><a class="nounderline abstract_t">Yu NC, Haug MT 3rd, Khan SU, et al. Does the donor-recipient ABO blood group compatibility status predict subsequent lung transplantation outcomes? J Heart Lung Transplant 1999; 18:764.</a></li><li><a class="nounderline abstract_t">Taghavi S, Jayarajan SN, Furuya  Y, et al. Single Lung Transplantation with ABO Compatible Donors Results in Excellent Outcomes. J Heart Lung Transplant 2014.</a></li><li><a class="nounderline abstract_t">Taghavi S, Jayarajan SN, Furuya Y, et al. Single-lung transplantation with ABO-compatible donors results in excellent outcomes. J Heart Lung Transplant 2014; 33:822.</a></li><li><a class="nounderline abstract_t">Low M, Gregory G. Passenger lymphocyte syndrome after lung transplant. Blood 2012; 120:4122.</a></li><li><a class="nounderline abstract_t">Horlait G, Bulpa P, Evrard P. Passenger lymphocyte syndrome mimicking hemolytic uremic syndrome after lung transplantation. J Heart Lung Transplant 2013; 32:271.</a></li><li><a class="nounderline abstract_t">Angel LF, Levine DJ, Restrepo MI, et al. Impact of a lung transplantation donor-management protocol on lung donation and recipient outcomes. Am J Respir Crit Care Med 2006; 174:710.</a></li><li><a class="nounderline abstract_t">de Perrot M, Wigle DA, Pierre AF, et al. Bronchogenic carcinoma after solid organ transplantation. Ann Thorac Surg 2003; 75:367.</a></li><li><a class="nounderline abstract_t">Berman M, Goldsmith K, Jenkins D, et al. Comparison of outcomes from smoking and nonsmoking donors: thirteen-year experience. Ann Thorac Surg 2010; 90:1786.</a></li><li><a class="nounderline abstract_t">Bonser RS, Taylor R, Collett D, et al. Effect of donor smoking on survival after lung transplantation: a cohort study of a prospective registry. Lancet 2012; 380:747.</a></li><li><a class="nounderline abstract_t">Taghavi S, Jayarajan SN, Komaroff E, et al. Single-lung transplantation can be performed with acceptable outcomes using selected donors with heavy smoking history. J Heart Lung Transplant 2013; 32:1005.</a></li><li><a class="nounderline abstract_t">Taghavi S, Jayarajan S, Komaroff E, et al. Double-lung transplantation can be safely performed using donors with heavy smoking history. Ann Thorac Surg 2013; 95:1912.</a></li><li><a class="nounderline abstract_t">Anis KH, Weinrauch LA, D'Elia JA. Effects of Smoking on Solid Organ Transplantation Outcomes. Am J Med 2019; 132:413.</a></li><li><a class="nounderline abstract_t">Healey PJ, Davis CL. Transmission of tumours by transplantation. Lancet 1998; 352:2.</a></li><li><a class="nounderline abstract_t">Fishman JA, Greenwald MA, Kuehnert MJ. Enhancing transplant safety: a new era in the microbiologic evaluation of organ donors? Am J Transplant 2007; 7:2652.</a></li><li><a class="nounderline abstract_t">Leard LE, Holm AM, Valapour M, et al. Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 2021; 40:1349.</a></li><li><a class="nounderline abstract_t">Ahmad O, Shafii AE, Mannino DM, et al. Impact of donor lung pathogenic bacteria on patient outcomes in the immediate post-transplant period. Transpl Infect Dis 2018; 20:e12986.</a></li><li><a class="nounderline abstract_t">Ridgeway AL, Warner GS, Phillips P, et al. Transmission of Mycobacterium tuberculosis to recipients of single lung transplants from the same donor. Am J Respir Crit Care Med 1996; 153:1166.</a></li><li class="breakAll">Council of Europe. Guide to the quality and safety of organs for transplantation. https://www.edqm.eu/en/guide-quality-and-safety-of-organs-for-transplantation (Accessed on October 03, 2022).</li><li><a class="nounderline abstract_t">Roberts SC, Ison MG. Donor-Derived Disease Transmission in Lung Transplantation. Current Pulmonology Reports 2020; 9:1.</a></li><li class="breakAll">U.S. Department of Health &amp; Human Services: Organ Procurement and Transplantation Network. Understanding the Risk of Transmission of HIV, Hepatitis B, and Hepatitis C from U.S. PHS Increased Risk Donors https://optn.transplant.hrsa.gov/media/2270/dtac_guidance_risks_201706.pdf (Accessed on February 15, 2018).</li><li><a class="nounderline abstract_t">Woolley AE, Singh SK, Goldberg HJ, et al. Heart and Lung Transplants from HCV-Infected Donors to Uninfected Recipients. N Engl J Med 2019; 380:1606.</a></li><li><a class="nounderline abstract_t">Theodoropoulos NM, La Hoz RM, Wolfe C, et al. Donor derived hepatitis B virus infection: Analysis of the Organ Procurement &amp; Transplantation Network/United Network for Organ Sharing Ad Hoc Disease Transmission Advisory Committee. Transpl Infect Dis 2021; 23:e13458.</a></li><li><a class="nounderline abstract_t">Huprikar S, Danziger-Isakov L, Ahn J, et al. Solid organ transplantation from hepatitis B virus-positive donors: consensus guidelines for recipient management. Am J Transplant 2015; 15:1162.</a></li><li><a class="nounderline abstract_t">Hartwig MG, Patel V, Palmer SM, et al. Hepatitis B core antibody positive donors as a safe and effective therapeutic option to increase available organs for lung transplantation. Transplantation 2005; 80:320.</a></li><li><a class="nounderline abstract_t">Shitrit AB, Kramer MR, Bakal I, et al. Lamivudine prophylaxis for hepatitis B virus infection after lung transplantation. Ann Thorac Surg 2006; 81:1851.</a></li><li><a class="nounderline abstract_t">Russo FP, Viganò M, Stock P, et al. HBV-positive and HIV-positive organs in transplantation: A clinical guide for the hepatologist. J Hepatol 2022; 77:503.</a></li><li class="breakAll">Organ Procurement and Transplantation Network. Guidance for organ donation and transplantation professionals regarding the Zika virus https://optn.transplant.hrsa.gov/news/guidance-for-organ-donation-and-transplantation-professionals-regarding-the-zika-virus/. (Accessed on March 14, 2016).</li><li><a class="nounderline abstract_t">Silveira FP, Campos SV. The Zika epidemics and transplantation. J Heart Lung Transplant 2016; 35:560.</a></li><li class="breakAll">ISHLT COVID-19 Task Force. Guidance Document for Cardiothoracic Transplantation and VAD Centers. https://ishlt.org/ishlt/media/documents/SARS-CoV-2_-Guidance-for-Cardiothoracic-Transplant-and-VAD-centers.pdf (Accessed on May 29, 2020).</li><li><a class="nounderline abstract_t">Kaul DR, Valesano AL, Petrie JG, et al. Donor to recipient transmission of SARS-CoV-2 by lung transplantation despite negative donor upper respiratory tract testing. Am J Transplant 2021; 21:2885.</a></li><li><a class="nounderline abstract_t">Kumar D, Humar A, Keshavjee S, Cypel M. A call to routinely test lower respiratory tract samples for SARS-CoV-2 in lung donors. Am J Transplant 2021; 21:2623.</a></li><li class="breakAll">Notice of OPTN Emergency Policy Change. Lower Respiratory SARS-CoV-2 Testing for Lung Donors. 2021. https://optn.transplant.hrsa.gov/media/4576/policy_notice_lunglowerrespiratorytesting_20210426.pdf (Accessed on September 13, 2021).</li><li><a class="nounderline abstract_t">Holm AM, Mehra MR, Courtwright A, et al. Ethical considerations regarding heart and lung transplantation and mechanical circulatory support during the COVID-19 pandemic: an ISHLT COVID-19 Task Force statement. J Heart Lung Transplant 2020; 39:619.</a></li><li><a class="nounderline abstract_t">Eichenberger EM, Coniglio AC, Milano C, et al. Transplanting thoracic COVID-19 positive donors: An institutional protocol and report of the first 14 cases. J Heart Lung Transplant 2022; 41:1376.</a></li><li><a class="nounderline abstract_t">Anraku M, Cameron MJ, Waddell TK, et al. Impact of human donor lung gene expression profiles on survival after lung transplantation: a case-control study. Am J Transplant 2008; 8:2140.</a></li><li><a class="nounderline abstract_t">Cypel M, Liu M, Rubacha M, et al. Functional repair of human donor lungs by IL-10 gene therapy. Sci Transl Med 2009; 1:4ra9.</a></li></ol></div><div id="topicVersionRevision">Topic 4664 Version 55.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11309637" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : The diagnosis of brain death.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11309637" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : The diagnosis of brain death.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20124892" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : The circulatory-respiratory determination of death in organ donation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32921583" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Geographic and temporal patterns of growth in the utilization of donation after circulatory death donors for lung transplantation in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7482979" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Statement on non-heart-beating donor programs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25420844" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Belgian modified classification of Maastricht for donors after circulatory death.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11265950" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Transplantation of lungs from a non-heart-beating donor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23815722" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : An official American Thoracic Society/International Society for Heart and Lung Transplantation/Society of Critical Care Medicine/Association of Organ and Procurement Organizations/United Network of Organ Sharing Statement: ethical and policy considerations in organ donation after circulatory determination of death.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35370034" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : ISHLT position paper on thoracic organ transplantation in controlled donation after circulatory determination of death (cDCD).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35227627" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Lung transplant outcome following donation after euthanasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31160497" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Deceased organ and tissue donation after medical assistance in dying and other conscious and competent donors: guidance for policy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35108446" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Outcomes of lung transplantation from organ donation after medical assistance in dying: First North American experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35266615" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : OPTN/SRTR 2020 Annual Data Report: Lung.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16426312" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Report of a National Conference on Donation after cardiac death.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11546995" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Recommendations for nonheartbeating organ donation. A position paper by the Ethics Committee, American College of Critical Care Medicine, Society of Critical Care Medicine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33635355" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Expanding controlled donation after the circulatory determination of death: statement from an international collaborative.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36695685" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : American Society of Transplant Surgeons recommendations on best practices in donation after circulatory death organ procurement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7289009" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Guidelines for the determination of death. Report of the medical consultants on the diagnosis of death to the President's Commission for the Study of Ethical Problems in Medicine and Biomedical and Behavioral Research.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10641238" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : The dead donor rule.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19624569" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : ASTS recommended practice guidelines for controlled donation after cardiac death organ procurement and transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34334301" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Early US experience with cardiac donation after circulatory death (DCD) using normothermic regional perfusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35072337" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Response to American College of Physician's statement on the ethics of transplant after normothermic regional perfusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35510751" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : cDCDD-NRP is consistent with US legal standards for determining death.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37665984" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Standards and Ethics Issues in the Determination of Death: A Position Paper From the American College of Physicians.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25638297" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Lung transplantation from donation after cardiocirculatory death: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26454741" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : International Society for Heart and Lung Transplantation Donation After Circulatory Death Registry Report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35300913" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Donation after circulatory death donors in high-risk recipients undergoing bilateral lung transplantation: An ISHLT database registry analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25777057" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Long-term results after lung transplantation using organs from circulatory death donors: a propensity score-matched analysis†.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23777361" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Use of lung allografts from brain-dead donors after cardiopulmonary arrest and resuscitation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21799025" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Lung size mismatch in bilateral lung transplantation is associated with allograft function and bronchiolitis obliterans syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22036314" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Parameters of donor-recipient size mismatch and survival after bilateral lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19379997" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Matching donor to recipient in lung transplantation: How much does size matter?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19201337" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Impact of graft volume reduction for oversized grafts after lung transplantation on outcome in recipients with end-stage restrictive pulmonary diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34021318" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Graft reduction surgery is associated with poorer outcome after lung transplantation: a single-centre propensity score-matched analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25978154" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Management of the Potential Organ Donor in the ICU: Society of Critical Care Medicine/American College of Chest Physicians/Association of Organ Procurement Organizations Consensus Statement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25132970" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Lung donor selection criteria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36764887" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Development and validation of the lung donor (LUNDON) acceptability score for pulmonary transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15982604" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Donor infection: an opinion on lung donor utilization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12243497" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Increased transplanted organs from the use of a standardized donor management protocol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14570373" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Liberalization of donor criteria in lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15110623" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : "Twinning procedure" in lung transplantation: influence of graft ischemia on survival and incidence of complications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15848310" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Extended donor criteria for lung transplantation--a clinical reality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15848311" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Extended donor lungs: eleven years experience in a consecutive series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20494023" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Guidelines for donor lung selection: time for revision?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23953918" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Extended criteria donor lungs and clinical outcome: results of an alternative allocation algorithm.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27234027" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : The use of extended criteria donors decreases one-year survival in high-risk lung recipients: A review of the United Network of Organ Sharing Database.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14585380" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : A review of lung transplant donor acceptability criteria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11124490" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Liberalization of donor criteria may expand the donor pool without adverse consequence in lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11882811" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Marginal donor lungs: a reassessment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23664760" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : The use of lung donors older than 55 years: a review of the United Network of Organ Sharing database.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26186805" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Survival and spirometry outcomes after lung transplantation from donors aged 70 years and older.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25301358" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Influence of donor and recipient age in lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24034167" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Donor age and early graft failure after lung transplantation: a cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29129267" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Does Donor Age and Double Versus Single Lung Transplant Affect Survival of Young Recipients?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30444994" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : The Impact of Donor and Recipient Age: Older Lung Transplant Recipients Do Not Require Younger Lungs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32492441" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Predictors of Older Donor Lung Use: Are We Too Good at Saying No?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9458026" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Donor-derived antibodies and hemolysis after ABO-compatible but nonidentical heart-lung and lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10512522" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Does the donor-recipient ABO blood group compatibility status predict subsequent lung transplantation outcomes?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Single Lung Transplantation with ABO Compatible Donors Results in Excellent Outcomes</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24880825" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Single-lung transplantation with ABO-compatible donors results in excellent outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23304710" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Passenger lymphocyte syndrome after lung transplant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23265912" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Passenger lymphocyte syndrome mimicking hemolytic uremic syndrome after lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16799075" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Impact of a lung transplantation donor-management protocol on lung donation and recipient outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12607641" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Bronchogenic carcinoma after solid organ transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21095311" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Comparison of outcomes from smoking and nonsmoking donors: thirteen-year experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22647758" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Effect of donor smoking on survival after lung transplantation: a cohort study of a prospective registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24054808" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Single-lung transplantation can be performed with acceptable outcomes using selected donors with heavy smoking history.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23623543" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Double-lung transplantation can be safely performed using donors with heavy smoking history.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30452885" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Effects of Smoking on Solid Organ Transplantation Outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9800732" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Transmission of tumours by transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17983389" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Enhancing transplant safety: a new era in the microbiologic evaluation of organ donors?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34419372" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30171789" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Impact of donor lung pathogenic bacteria on patient outcomes in the immediate post-transplant period.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8630561" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Transmission of Mycobacterium tuberculosis to recipients of single lung transplants from the same donor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8630561" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Transmission of Mycobacterium tuberculosis to recipients of single lung transplants from the same donor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Donor-Derived Disease Transmission in Lung Transplantation</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Donor-Derived Disease Transmission in Lung Transplantation</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30946553" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Heart and Lung Transplants from HCV-Infected Donors to Uninfected Recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32894634" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Donor derived hepatitis B virus infection: Analysis of the Organ Procurement&amp;Transplantation Network/United Network for Organ Sharing Ad Hoc Disease Transmission Advisory Committee.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25707744" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Solid organ transplantation from hepatitis B virus-positive donors: consensus guidelines for recipient management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16082326" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Hepatitis B core antibody positive donors as a safe and effective therapeutic option to increase available organs for lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16631684" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Lamivudine prophylaxis for hepatitis B virus infection after lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35398460" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : HBV-positive and HIV-positive organs in transplantation: A clinical guide for the hepatologist.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35398460" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : HBV-positive and HIV-positive organs in transplantation: A clinical guide for the hepatologist.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27197772" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : The Zika epidemics and transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27197772" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : The Zika epidemics and transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33565705" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Donor to recipient transmission of SARS-CoV-2 by lung transplantation despite negative donor upper respiratory tract testing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33756058" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : A call to routinely test lower respiratory tract samples for SARS-CoV-2 in lung donors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33756058" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : A call to routinely test lower respiratory tract samples for SARS-CoV-2 in lung donors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32505492" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Ethical considerations regarding heart and lung transplantation and mechanical circulatory support during the COVID-19 pandemic: an ISHLT COVID-19 Task Force statement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35871114" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Transplanting thoracic COVID-19 positive donors: An institutional protocol and report of the first 14 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18727701" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Impact of human donor lung gene expression profiles on survival after lung transplantation: a case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20368171" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Functional repair of human donor lungs by IL-10 gene therapy.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
